LabCorp Licenses DNA-Methylation IP From Veridex for a Prostate Cancer Dx | GenomeWeb
NEW YORK (GenomeWeb News) — LabCorp today said it has licensed DNA-methylation technology from Veridex that may help it develop and market an assay to detect prostate cancer.
 
The reference lab giant said its assay will quantify in human samples the level of the gene GST-Pi, which has been linked to prostate cancer.
 
If the technology is used in conjunction with histopathology testing it may “provide a more sensitive and accurate detection of prostate cancer than histology alone,” LabCorp said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.